2026년 9월 15일•3분 읽기
Korean Pharma Secures Minimal Buffer Amid Drug Price Cut Reassessment
The Korean pharmaceutical and biotech sector has secured a limited buffer period as the government delays and adjusts price‑cut criteria for re‑evaluated listed drugs.